Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) EBITDA Margin (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBITDA Margin for 5 consecutive years, with 4834.11% as the latest value for Q2 2025.

  • For Q2 2025, EBITDA Margin fell 99707.0% year-over-year to 4834.11%; the TTM value through Dec 2025 reached 9107.4%, down 220409.0%, while the annual FY2023 figure was 1591.77%, N/A changed from the prior year.
  • EBITDA Margin hit 4834.11% in Q2 2025 for Kezar Life Sciences, down from 5080.4% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 8869.81% in Q4 2021 and bottomed at 364.67% in Q3 2023.
  • Average EBITDA Margin over 5 years is 5601.58%, with a median of 5964.43% recorded in 2022.
  • Year-over-year, EBITDA Margin surged 95578bps in 2023 and then crashed -112571bps in 2024.
  • Kezar Life Sciences' EBITDA Margin stood at 8869.81% in 2021, then crashed by -32bps to 6001.1% in 2022, then crashed by -106bps to 364.67% in 2023, then surged by 1699bps to 5831.17% in 2024, then dropped by -17bps to 4834.11% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 4834.11%, 5080.4%, and 5831.17% for Q2 2025, Q1 2025, and Q2 2024 respectively.